Concert Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CNCE)

$19.24 -0.91 (-4.52 %)
(As of 01/17/2018 01:54 AM ET)
Previous Close$20.15
Today's Range$18.90 - $20.77
52-Week Range$8.61 - $30.71
Volume1.45 million shs
Average Volume738,490 shs
Market Capitalization$458.87 million
P/E Ratio5.17
Dividend YieldN/A
Beta1.67

About Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals logoConcert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company's deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas. Its product candidates include AVP-786, CTP-656, CTP-730, CTP-543 and JZP-386. The Company's product candidate, CTP-656, is a next generation potentiator that it is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. CTP-543 was discovered by applying Concert's deuterium chemistry technology to modify ruxolitinib. AVP-786 is a combination of a dextromethorphan and an ultra-low dose of quinidine. CTP-730 is a phosphodiesterase 4 (PDE4) inhibitor that has potential for the treatment of various inflammatory diseases.

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CNCE
CUSIPN/A
Phone781-860-0045

Debt

Debt-to-Equity RatioN/A
Current Ratio28.18%
Quick Ratio28.18%

Price-To-Earnings

Trailing P/E Ratio5.17204301075269
Forward P/E Ratio4.69
P/E GrowthN/A

Sales & Book Value

Annual Sales$170,000.00
Price / Sales2,577.03
Cash FlowN/A
Price / CashN/A
Book Value$3.84 per share
Price / Book5.01

Profitability

Trailing EPS$3.72
Net Income$-50,720,000.00
Net Margins62.31%
Return on Equity-51.48%
Return on Assets-42.46%

Miscellaneous

Employees69
Outstanding Shares22,770,000

Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) issued its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported ($0.70) EPS for the quarter, missing analysts' consensus estimates of ($0.54) by $0.16. Concert Pharmaceuticals had a negative return on equity of 51.48% and a net margin of 62.31%. View Concert Pharmaceuticals' Earnings History.

Where is Concert Pharmaceuticals' stock going? Where will Concert Pharmaceuticals' stock price be in 2018?

4 Wall Street analysts have issued twelve-month price objectives for Concert Pharmaceuticals' shares. Their predictions range from $21.00 to $27.00. On average, they expect Concert Pharmaceuticals' share price to reach $24.00 in the next year. View Analyst Ratings for Concert Pharmaceuticals.

What are Wall Street analysts saying about Concert Pharmaceuticals stock?

Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (11/15/2017)
  • 2. HC Wainwright analysts commented, "de-risked platform for drug discovery" along with a lead clinical asset for alopecia areata.Over the past five years, the company has leveraged its proprietary platform as a source for external partnerships and has had four validating partnership deals, the analyst continued. The most recent partnership related to the acquisition of CTP-656 which is under FTC review before the final close date in October.While there is "little clarity" into the review process of CTP-656, investors should believe in the "fundamental value of a deuterated potentiator to the many players still eager to assemble the best-in-class triple combo for cystic fibrosis," Fein stated.CTP-543The recent clinical hold lift of Concert's CTP-543, a deuterated ruxolitinib (a JAK1/2 inhibitor), for the treatment of adults with moderate-to-severe AA, should be viewed as the removal of an overhang and clears a path for a phase 2a readout in the bottom half of 2018, Fein also noted."We suspect that this clinical hold may [have] less to do with endogenous factors (e.g., the compound or trial itself), and more to do with exogenous factors (e.g., the evolving sphere of research around AA field and JAK inhibitor research broadly)," he wrote. "As such, we applaud management's attitude in starting an open and conciliatory dialogue with the agency early on to prevent any possible negative downstream scenarios and allow the data to speak for itself." (7/24/2017)

Who are some of Concert Pharmaceuticals' key competitors?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the folowing people:

  • Richard H. Aldrich, Chairman of the Board, Co-Founder (Age 62)
  • Roger D. Tung Ph.D., President, Chief Executive Officer, Co-Founder, Director (Age 57)
  • Ryan Lynch, Principal Financial Officer, Principal Accounting Officer
  • Marc Becker, Chief Financial Officer (Age 45)
  • Nancy Stuart, Chief Operating Officer (Age 55)
  • Ian Robert Silverman, Senior Vice President and General Counsel (Age 63)
  • James Cassella, , Senior Vice President, chief development officer
  • Christine Boisclair, Vice President - Regulatory Affairs
  • Scott Weintraub, Vice President - Commercial and Product Strategy
  • Thomas G. Auchincloss Jr., Director (Age 52)

Who owns Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Convergence Investment Partners LLC (0.12%). Company insiders that own Concert Pharmaceuticals stock include Roger D Tung, Ronald W Barrett, Ryan Lynch, Thomas G Auchincloss and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.

Who bought Concert Pharmaceuticals stock? Who is buying Concert Pharmaceuticals stock?

Concert Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Convergence Investment Partners LLC. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Roger D Tung, Thomas G Auchincloss and Value Fund L P Biotechnology. View Insider Buying and Selling for Concert Pharmaceuticals.

How do I buy Concert Pharmaceuticals stock?

Shares of Concert Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of Concert Pharmaceuticals stock can currently be purchased for approximately $19.24.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $458.87 million and generates $170,000.00 in revenue each year. The biotechnology company earns $-50,720,000.00 in net income (profit) each year or $3.72 on an earnings per share basis. Concert Pharmaceuticals employs 69 workers across the globe.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 99 HAYDEN AVENUE SUITE 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]


MarketBeat Community Rating for Concert Pharmaceuticals (CNCE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  106 (Vote Underperform)
Total Votes:  293
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Concert Pharmaceuticals (NASDAQ:CNCE) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.753.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.00$24.75$26.75$28.00
Price Target Upside: 19.11% upside40.07% upside83.47% upside105.28% upside

Concert Pharmaceuticals (NASDAQ:CNCE) Consensus Price Target History

Price Target History for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (NASDAQ:CNCE) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/12/2018Stifel NicolausReiterated RatingBuy$27.00N/AView Rating Details
1/12/2018MizuhoDowngradeBuy -> Neutral$23.00HighView Rating Details
11/10/2017HC WainwrightReiterated RatingBuy$21.00N/AView Rating Details
6/12/2017AegisReiterated RatingBuy$25.00LowView Rating Details
10/28/2016Roth CapitalSet Price TargetBuy$32.00N/AView Rating Details
9/7/2016Brean CapitalReiterated RatingBuy$25.00N/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$28.00 -> $24.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $24.00N/AView Rating Details
(Data available from 1/17/2016 forward)

Earnings

Concert Pharmaceuticals (NASDAQ:CNCE) Earnings History and Estimates Chart

Earnings by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (NASDAQ CNCE) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.54)($0.70)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.62)($0.58)$0.20 million$0.02 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.54)($0.60)$0.02 millionViewListenView Earnings Details
3/6/2017Q4 2016($0.66)($0.54)$0.02 millionViewListenView Earnings Details
11/8/2016Q316($0.63)($0.51)$0.06 million$0.03 millionViewListenView Earnings Details
8/9/2016Q2($0.63)($0.60)$0.06 million$0.07 millionViewN/AView Earnings Details
5/5/2016Q116($0.45)($0.63)$1.66 million$0.06 millionViewN/AView Earnings Details
3/1/2016Q415($0.05)$0.03$11.24 million$10.30 millionViewN/AView Earnings Details
11/5/2015Q315($0.41)($0.39)$4.50 million$1.70 millionViewListenView Earnings Details
8/5/2015Q215($0.46)($0.40)$1.66 million$3.25 millionViewListenView Earnings Details
5/8/2015Q115($0.38)($0.48)$2.70 million$1.30 millionViewListenView Earnings Details
2/27/2015Q414($0.60)($0.48)$1.77 million$1.31 millionViewN/AView Earnings Details
11/12/2014Q314($0.45)($0.43)$1.67 million$4.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.40)($0.45)$1.30 million$1.20 millionViewN/AView Earnings Details
5/14/2014Q114($0.49)($0.76)$0.44 million$1.61 millionViewN/AView Earnings Details
3/31/2014Q4 2013($4.64)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Concert Pharmaceuticals (NASDAQ:CNCE) Earnings Estimates

Current Year EPS Consensus Estimate: $4.1 EPS
Next Year EPS Consensus Estimate: $-2.35 EPS

Dividends

Dividend History for Concert Pharmaceuticals (NASDAQ:CNCE)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Concert Pharmaceuticals (NASDAQ CNCE) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 10.10%
Institutional Ownership Percentage: 65.29%
Insider Trades by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)
Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Concert Pharmaceuticals (NASDAQ CNCE) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/19/2017Value Fund L P BiotechnologyInsiderSell1,282,856$26.65$34,188,112.40View SEC Filing  
12/4/2017Ronald W BarrettDirectorSell14,156$24.70$349,653.203,539View SEC Filing  
10/19/2017Value Fund L P BiotechnologyInsiderBuy331,916$15.84$5,257,549.44View SEC Filing  
9/14/2017Ryan LynchInsiderSell3,500$14.51$50,785.009,500View SEC Filing  
5/12/2016Thomas G AuchinclossDirectorBuy2,000$10.11$20,220.002,000View SEC Filing  
5/11/2016Roger D TungCEOBuy19,610$10.55$206,885.50538,965View SEC Filing  
12/16/2015Wilfred E JaegerDirectorSell10,360$19.57$202,745.20View SEC Filing  
12/15/2015Wilfred E JaegerDirectorSell54,572$20.10$1,096,897.20View SEC Filing  
12/14/2015Pauline McgowanVPSell498$20.07$9,994.86View SEC Filing  
12/14/2015Wilfred E JaegerDirectorSell3,922$20.09$78,792.98View SEC Filing  
11/9/2015Ronald W. BarrettDirectorSell17,699$22.27$394,156.73View SEC Filing  
11/2/2015Nancy StuartCOOSell23,216$24.29$563,916.6425,004View SEC Filing  
9/18/2015Robert SilvermanVPSell10,000$20.00$200,000.0010,000View SEC Filing  
9/10/2015Wilfred E JaegerDirectorSell120,000$18.22$2,186,400.00View SEC Filing  
8/18/2015Wilfred E JaegerDirectorSell760,000$15.81$12,015,600.00View SEC Filing  
8/13/2015Wilfred E JaegerDirectorSell92,215$16.75$1,544,601.25View SEC Filing  
8/12/2015Wilfred E JaegerDirectorSell97,785$17.49$1,710,259.65View SEC Filing  
6/8/2015Robert SilvermanVPSell5,000$16.35$81,750.00View SEC Filing  
3/11/2015Nancy StuartCOOSell46,430$15.00$696,450.00View SEC Filing  
3/11/2015Pauline McgowanVPSell5,973$16.00$95,568.00View SEC Filing  
3/10/2015Pauline McgowanVPSell22,122$13.90$307,495.80View SEC Filing  
11/18/2014Three Arch Management Iv, L.L.DirectorSell250,000$12.29$3,072,500.00View SEC Filing  
2/20/2014Skyline Venture Partners QualiMajor ShareholderBuy150,000$14.00$2,100,000.00View SEC Filing  
2/19/2014Life Science Ventures Vi G TvmDirectorBuy89,000$14.00$1,246,000.00View SEC Filing  
2/19/2014Plc GlaxosmithklineMajor ShareholderBuy35,000$14.00$490,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Concert Pharmaceuticals (NASDAQ CNCE) News Headlines

Source:
DateHeadline
Concert Pharma shares hit low note on patent challenge denial - Boston Business JournalConcert Pharma shares hit low note on patent challenge denial - Boston Business Journal
www.bizjournals.com - January 16 at 4:52 PM
Concert Pharmaceuticals (CNCE) Given Buy Rating at Stifel NicolausConcert Pharmaceuticals (CNCE) Given Buy Rating at Stifel Nicolaus
www.americanbankingnews.com - January 13 at 8:00 PM
Concert Pharma (CNCE) Reports Patent Trial and Appeal Board Denies Petition on 335 PetitionConcert Pharma (CNCE) Reports Patent Trial and Appeal Board Denies Petition on '335 Petition
www.streetinsider.com - January 13 at 9:54 AM
Concert Pharma Drops On Patent Litigation Setback; Mizuho DowngradesConcert Pharma Drops On Patent Litigation Setback; Mizuho Downgrades
finance.yahoo.com - January 13 at 9:54 AM
Health Care Sector Update for 01/12/2018: PSTI,GSK,CNCE,INCY - NasdaqHealth Care Sector Update for 01/12/2018: PSTI,GSK,CNCE,INCY - Nasdaq
www.nasdaq.com - January 12 at 4:43 PM
Mizuho Lowers Concert Pharmaceuticals (CNCE) to NeutralMizuho Lowers Concert Pharmaceuticals (CNCE) to Neutral
www.americanbankingnews.com - January 12 at 12:38 PM
Concert Pharmaceuticals Inc. (CNCE) Is Falling After PGR Petition DeniedConcert Pharmaceuticals Inc. (CNCE) Is Falling After PGR Petition Denied
www.nasdaq.com - January 12 at 10:03 AM
FDA Grants Fast Track Designation to Concert Pharmaceuticals’ CTP-543 for the Treatment of Alopecia AreataFDA Grants Fast Track Designation to Concert Pharmaceuticals’ CTP-543 for the Treatment of Alopecia Areata
finance.yahoo.com - January 12 at 10:03 AM
Concert Pharmaceuticals Inc (CNCE) Receives Average Recommendation of "Buy" from AnalystsConcert Pharmaceuticals Inc (CNCE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 9 at 7:44 PM
Zacks: Brokerages Anticipate Concert Pharmaceuticals Inc (CNCE) Will Post Quarterly Sales of $8.10 MillionZacks: Brokerages Anticipate Concert Pharmaceuticals Inc (CNCE) Will Post Quarterly Sales of $8.10 Million
www.americanbankingnews.com - January 6 at 4:18 AM
Concert Pharmaceuticals (CNCE) Lifted to "C+" at TheStreetConcert Pharmaceuticals (CNCE) Lifted to "C+" at TheStreet
www.americanbankingnews.com - December 30 at 4:22 PM
ETFs with exposure to Concert Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Concert Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 27 at 5:12 PM
Concert Pharmaceuticals (CNCE) Rating Lowered to Buy at BidaskClubConcert Pharmaceuticals (CNCE) Rating Lowered to Buy at BidaskClub
www.americanbankingnews.com - December 23 at 2:10 PM
Insider Selling: Concert Pharmaceuticals Inc (CNCE) Insider Sells 1,282,856 Shares of StockInsider Selling: Concert Pharmaceuticals Inc (CNCE) Insider Sells 1,282,856 Shares of Stock
www.americanbankingnews.com - December 21 at 8:28 PM
Concert Pharmaceuticals Inc. (CNCE) Has Risen To A New High After New CFO NamedConcert Pharmaceuticals Inc. (CNCE) Has Risen To A New High After New CFO Named
www.nasdaq.com - December 20 at 10:03 AM
$8.10 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter$8.10 Million in Sales Expected for Concert Pharmaceuticals Inc (CNCE) This Quarter
www.americanbankingnews.com - December 20 at 2:52 AM
UBS Reaffirms "Buy" Rating for Concert Pharmaceuticals (CNCE)UBS Reaffirms "Buy" Rating for Concert Pharmaceuticals (CNCE)
www.americanbankingnews.com - December 19 at 7:26 AM
Concert Pharmaceuticals Inc (CNCE) Expected to Post Earnings of -$0.18 Per ShareConcert Pharmaceuticals Inc (CNCE) Expected to Post Earnings of -$0.18 Per Share
www.americanbankingnews.com - December 18 at 9:20 PM
Concert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial OfficerConcert Pharmaceuticals Announces the Appointment of Marc Becker as Chief Financial Officer
finance.yahoo.com - December 18 at 10:21 AM
Concert Pharmaceuticals Inc (CNCE) Given Average Rating of "Buy" by BrokeragesConcert Pharmaceuticals Inc (CNCE) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - December 15 at 5:26 PM
Concert Pharmaceuticals: Materialized Income With Reasonable Valuation - Seeking AlphaConcert Pharmaceuticals: Materialized Income With Reasonable Valuation - Seeking Alpha
seekingalpha.com - December 14 at 5:25 PM
Concert Pharmaceuticals to Be Added to NASDAQ Biotechnology IndexConcert Pharmaceuticals to Be Added to NASDAQ Biotechnology Index
finance.yahoo.com - December 13 at 10:20 AM
ETFs with exposure to Concert Pharmaceuticals, Inc. : December 11, 2017ETFs with exposure to Concert Pharmaceuticals, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 5:02 PM
BidaskClub Upgrades Concert Pharmaceuticals (CNCE) to Strong-BuyBidaskClub Upgrades Concert Pharmaceuticals (CNCE) to Strong-Buy
www.americanbankingnews.com - December 9 at 9:50 AM
Ronald W. Barrett Sells 14,156 Shares of Concert Pharmaceuticals Inc (CNCE) StockRonald W. Barrett Sells 14,156 Shares of Concert Pharmaceuticals Inc (CNCE) Stock
www.americanbankingnews.com - December 6 at 5:46 PM
Concert Pharmaceuticals: Thoughts Going Into 2018 - Seeking Alpha - Seeking AlphaConcert Pharmaceuticals: Thoughts Going Into 2018 - Seeking Alpha - Seeking Alpha
seekingalpha.com - December 5 at 10:43 AM
Concert Pharmaceuticals Inc (CNCE) Expected to Announce Quarterly Sales of $8.10 MillionConcert Pharmaceuticals Inc (CNCE) Expected to Announce Quarterly Sales of $8.10 Million
www.americanbankingnews.com - December 2 at 2:50 AM
Celldex Therapeutics (CLDX) vs. Concert Pharmaceuticals (CNCE) Financial ContrastCelldex Therapeutics (CLDX) vs. Concert Pharmaceuticals (CNCE) Financial Contrast
www.americanbankingnews.com - December 1 at 9:32 PM
ETFs with exposure to Concert Pharmaceuticals, Inc. : December 1, 2017ETFs with exposure to Concert Pharmaceuticals, Inc. : December 1, 2017
finance.yahoo.com - December 1 at 5:18 PM
Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017Concert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 30, 2017
finance.yahoo.com - November 30 at 10:28 AM
Concert Pharmaceuticals, Inc. (CNCE) Receives Consensus Rating of "Hold" from AnalystsConcert Pharmaceuticals, Inc. (CNCE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - November 20 at 5:44 PM
Concert Pharma (CNCE) Presents At Jefferies 2017 London Healthcare Conference - SlideshowConcert Pharma (CNCE) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
seekingalpha.com - November 17 at 9:35 PM
Concert Pharmaceuticals Sees Unusually High Options Volume (CNCE)Concert Pharmaceuticals Sees Unusually High Options Volume (CNCE)
www.americanbankingnews.com - November 17 at 1:26 AM
Concert Pharmaceuticals, Inc. (CNCE) Stock Rating Upgraded by Zacks Investment ResearchConcert Pharmaceuticals, Inc. (CNCE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 15 at 9:00 PM
 Analysts Expect Concert Pharmaceuticals, Inc. (CNCE) Will Announce Earnings of $2.63 Per Share Analysts Expect Concert Pharmaceuticals, Inc. (CNCE) Will Announce Earnings of $2.63 Per Share
www.americanbankingnews.com - November 12 at 8:38 AM
Concert Pharmaceuticals, Inc. (CNCE) Rating Reiterated by HC WainwrightConcert Pharmaceuticals, Inc. (CNCE) Rating Reiterated by HC Wainwright
www.americanbankingnews.com - November 12 at 12:58 AM
Concert Pharmaceuticals (CNCE) CEO Roger Tung on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaConcert Pharmaceuticals' (CNCE) CEO Roger Tung on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 10 at 5:22 AM
Concert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company UpdateConcert Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Company Update
finance.yahoo.com - November 10 at 5:22 AM
Concert Pharmaceuticals, Inc. to Host Earnings CallConcert Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - November 10 at 5:22 AM
Edited Transcript of CNCE earnings conference call or presentation 9-Nov-17 1:30pm GMTEdited Transcript of CNCE earnings conference call or presentation 9-Nov-17 1:30pm GMT
finance.yahoo.com - November 10 at 5:22 AM
Concert posts 3Q profitConcert posts 3Q profit
finance.yahoo.com - November 10 at 5:22 AM
Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial - Business Wire (press release)Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial - Business Wire (press release)
www.businesswire.com - November 6 at 11:36 PM
Concert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a TrialConcert Pharmaceuticals Announces Completion of Enrollment in First Cohort of CTP-543 Phase 2a Trial
finance.yahoo.com - November 6 at 6:35 PM
Is It The Right Time To Buy Concert Pharmaceuticals Inc (CNCE)?Is It The Right Time To Buy Concert Pharmaceuticals Inc (CNCE)?
finance.yahoo.com - November 6 at 6:35 PM
Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at ... - Business Wire (press release)Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at ... - Business Wire (press release)
www.businesswire.com - November 2 at 6:16 PM
Concert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor ConferencesConcert Pharmaceuticals to Report Third Quarter 2017 Financial Results on November 9, 2017, and Participate at Upcoming Investor Conferences
finance.yahoo.com - November 2 at 6:16 PM
Concert Pharmaceuticals, Inc. (CNCE) Scheduled to Post Earnings on MondayConcert Pharmaceuticals, Inc. (CNCE) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 9:14 AM
$20,000.00 in Sales Expected for Concert Pharmaceuticals, Inc. (CNCE) This Quarter$20,000.00 in Sales Expected for Concert Pharmaceuticals, Inc. (CNCE) This Quarter
www.americanbankingnews.com - October 25 at 9:54 PM
ATOS Catches Eyes, PTIE Gains, CNCE Hits Right Notes, SMMT Keeps SlidingATOS Catches Eyes, PTIE Gains, CNCE Hits Right Notes, SMMT Keeps Sliding
www.nasdaq.com - October 25 at 12:43 AM
Concert Pharmaceuticals, Inc. (CNCE) Lowered to "Sell" at Zacks Investment ResearchConcert Pharmaceuticals, Inc. (CNCE) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - October 24 at 5:28 PM

SEC Filings

Concert Pharmaceuticals (NASDAQ:CNCE) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Concert Pharmaceuticals (NASDAQ:CNCE) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Concert Pharmaceuticals (NASDAQ CNCE) Stock Chart for Wednesday, January, 17, 2018

Loading chart…

This page was last updated on 1/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.